FDA accepts Teva's new drug application for Copaxone.Pharmaceutical Industries Ltd. (Nasdaq:TEVIY) announced yesterday in Israel that the United States Food and Drug Administration United States Food and Drug Administration (FDA), n.pr a unit of the Public Health Service created to protect the health of the nation against impure and unsafe foods, drugs, and cosmetics. (FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. ) has accepted for official filing the Company's New Drug Application (NDA (Non Disclosure Agreement) An agreement signed between two parties that have to disclose confidential information to each other in order to do business. In general, the NDA states why the information is being divulged and stipulates that it cannot be used for any ) for Copaxone (Copolymer-1) which was resubmitted on October 11, 1995. Teva Pharmaceutical Industries Teva Pharmaceutical Industries Ltd. (Hebrew: טבע תעשיות פרמצבטיות בע"מ), NASDAQ: TEVA is an international pharmaceutical company headquartered in Ltd. develops, manufactures and markets pharmaceuticals, bulk pharmaceutical chemicals, medical disposables and other products. The largest supplier of such products in Israel, the Company also has manufacturing facilities in the United States and Western Europe with over 60 percent of its sales generated outside of Israel. CONTACT: Teva Pharmaceutical Industries, Ltd. Dan Suesskind, (011) 972-2-892-811 or Morgen-Walke Associates, Inc. Investor Relations: Donna N. Stein Press: Brian Maddox, 212/850-5600 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion